The company’s lead product candidate, PBI-0451, is a direct-acting, oral antiviral drug to treat and prevent SARS-CoV-2 infections.
Location: United States, California, Berkeley
Total raised: $250.61M
Investors 4
| Date | Name | Website |
| - | Foresite C... | foresiteca... |
| 18.11.2021 | Khosla Ven... | khoslavent... |
| 27.08.2021 | Y Combinat... | ycombinato... |
| - | Frazier Li... | frazierls.... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 27.12.2021 | - | $199M | - |
| 03.02.2021 | - | $51.61M | - |
Mentions in press and media 2
| Date | Title | Description |
| 10.01.2022 | Pardes Bioscience Nets $199M in SPAC Merger | Another one of San Diego’s promising young biotechs has gone public via Wall Street’s SPAC merger route. In late December, Carlsbad-based Pardes Biosciences merged with special purpose acquisition company FS Development Corp. II and began t... |
| 27.12.2021 | Carlsbad’s Pardes Biosciences nets $199M to keep pace in COVID-19 pill race | Carlsbad startup Pardes Biosciences, which has begun clinical trials for an experimental pill to treat COVID-19, went public on Monday raising $199 million through a Special Purpose Acquisition Company, or SPAC. Founded in February 2020 spe... |